Thursday, 11 June 2026 | 14:00 - 14:20
Bringing HER2 imaging to the clinic: from discovery to Phase 2b validation - Tony Lahoutte & Karine Clauwaert, UZ Brussels - Abscint
The speakers will share the development of ABSCINT’s HER2-targeted imaging platform, from concept to Phase 2b clinical validation in the HERMIA study. The results support its potential to reshape how HER2 expression is assessed and used in treatment decision-making.
2 speakers
CEO
ABSCINT
Head of the department of nuclear medicine
Vrije Universiteit Brussel